Cathie Wood’s ARK ETFs have published their daily trades for Wednesday, March 19th 2025, with a series of buys and sells across a range of innovative companies. Leading the purchases was a significant investment in Iridium Communications Inc (NASDAQ:IRDM), with ARK acquiring 164,481 shares valued at approximately $4.5 million. This move underscores ARK’s confidence in the satellite communications provider, which has seen consistent buying from the fund in recent days.
On the sell side, ARK made a notable exit from Meta Platforms Inc (NASDAQ:META), offloading 7,361 shares for a total of roughly $4.3 million. This trade follows a trend for ARK, which has been reducing its position in the social media giant throughout the past week. Additionally, the largest dollar-value trade of the day was a sell of UiPath Inc (NYSE:PATH), with ARK divesting 865,584 shares worth close to $9.3 million, further trimming its holdings in the automation software company.
In other significant trading activity, ARK continued to bolster its position in CRISPR Therapeutics AG (NASDAQ:CRSP), purchasing 24,324 shares across its ARKK and ARKG ETFs, totaling nearly $1 million. This genetic medicine company has been a recurring focus for ARK, indicating a strategic build-up in this sector.
ARK also showed interest in Absci Corp (NASDAQ:ABSI), a synthetic biology company, buying 436,880 shares through its ARKG ETF, amounting to over $1.3 million. This purchase aligns with ARK’s investment thesis on the disruptive potential of biotechnology.
Other buys included Intellia Therapeutics Inc (NASDAQ:NTLA) and 10X Genomics Inc (NASDAQ:TXG), with ARK acquiring 96,379 and 72,008 shares valued at approximately $886,000 and $757,000, respectively. Both companies are part of the growing genomics industry, which ARK has consistently supported.
Smaller trades, though not insignificant, included the selling of Amgen Inc (NASDAQ:AMGN), Illumina Inc (NASDAQ:ILMN), Pacific Biosciences of California Inc (NASDAQ:PACB), Prime Medicine Inc (NASDAQ:PRME), Repare Therapeutics Inc (NASDAQ:RPTX), and Veeva Systems Inc (NYSE:VEEV). These transactions ranged from around $15,000 to $478,000, indicating ARK’s dynamic portfolio management strategy.
Investors following Cathie Wood’s ARK ETFs will note the continued emphasis on genomic innovation and data analytics, as well as a cautious approach to larger tech companies, reflecting ARK’s forward-looking investment philosophy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.